FDA Approves Sarclisa with VRd | Int'l Myeloma Foundation
WEB1 day ago · According to a September 20, 2024, press release, the U.S. Food and Drug Administration (FDA) has "approved isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC) with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT)." This approval was based on results of the phase III IMROZ clinical trial ...
FDA Approves Sarclisa In Newly Diagnosed Transplant-Ineligible Multiple …
WEB15 hours ago · The Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) with Velcade (bortezomib), Revlimid (lenalidomide) and dexamethasone, a combination known as Isa-VRd, for the treatment of adults with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT, when a patient’s own stem cells are collected, stored and infused back into them ...
FDA Approves Isatuximab With VRd as First-Line Option for …
WEB15 hours ago · FDA approves isatuximab-irfc with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma. News release. FDA. September 20, 2024. Accessed September 20, 2024.
DARZALEX ® (daratumumab)-based quadruplet regimen receives …
WEB1 day ago · About multiple myeloma Multiple myeloma is currently an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow. 15,16 In multiple myeloma, these malignant plasma cells continue to proliferate, accumulating in the body and crowding …
IMF Launches Myelo: The First AI-Powered Chatbot for Myeloma …
WEB2 days ago · The IMF’s reliable InfoLine team is always ready to help address myeloma-related questions and consistently provides callers with the best information about multiple myeloma. You may contact the IMF InfoLine by emailing infoline@myeloma.org or by calling 1-800-452 CURE (2873) (U.S. and Canada), or 1 (818) 487-7455 (Worldwide).
Multiple Myeloma: Improved Prognosis With the Latest Treatments
WEBAug 16, 2023 · The overall five-year survival rate for people with active multiple myeloma in the United States has increased steadily over time, to more than 55% today. It’s important to remember that even the most recent statistics apply to many people who did not have access to the newer treatments.
Advances in multiple myeloma treatment - Mayo Clinic …
WEBMay 16, 2024 · Right now, there is no cure for the disease. But as Dr. Joselle Cook, a Mayo Clinic hematologist, explains, recent advances in treatment are helping people live longer. And as multiple myeloma research continues, a cure may someday be on the horizon.
Daratumumab Plus Standard Therapy for Multiple Myeloma
WEBJan 19, 2024 · A large randomized clinical trial for people newly diagnosed with multiple myeloma has found that adding the drug daratumumab (Darzalex) to a standard treatment regimen was more effective than that standard regimen on its own.
FDA’s Recent Approval of 2 CAR T-Cell Therapies a ‘Big Step …
WEBRye Brook, N.Y., April 16, 2024 – The U.S. Food and Drug Administration (FDA) recently approved the CAR T-cell therapies ciltacabtagene autoleucel (cilta-cel; Carvykti™) and idecabtagene vicleucel (ide-cel; Abecma®) for earlier …
FDA Approves First Cell-Based Gene Therapy for Adult Patients …
WEBMarch 27, 2021. The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded...